US › Healthcare

Biomea Fusion Inc (BMEA)

US · Healthcare · Biotechnology

$0.87+3.89%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-8.3M

EPS

$-0.12

EPS estimate

$-0.21

EPS came in at -0.12 against a street estimate of -0.21 — a beat of 42.9%.

Key statistics

Market cap

$102.7M

Forward P/E

0.0

P/B

8.60

Book value

$0.17

EPS (TTM)

$-0.29

52-week high

$2.24

52-week low

$0.87

50-day MA

$1.50

200-day MA

$1.41

Beta

-0.30

Analyst view

Analysts rate Biomea Fusion Inc a buy (7 buy, 0 hold, 1 sell out of 8) with an average price target of $7.00.

Shareholding

Insiders

7.15%

Institutions

40.02%

Largest institutional holders

Fund	Stake
FMR Inc	12.16%
Vanguard Capital Management, LLC	3.90%
Marshall Wace Asset Management Ltd	2.83%
Aisling Capital Management LP	2.83%
Renaissance Technologies Corp	2.01%
Fideuram - Intesa Sanpaolo Private Banking Spa	1.00%
BlackRock Inc	0.99%
Geode Capital Management, LLC	0.98%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Biomea Fusion Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.